FDA/The Osteosarcoma Institute (OSI) Workshop
Meeting information for FDA/The Osteosarcoma Institute (OSI) Workshop
Related Articles
FDA Approves First Immunotherapy for Recurrent Respiratory Papillomatosis
FDA approved Papzimeos, the first immunotherapy for use in adults with recurrent respiratory papillomatosis.
Certain Left Heart Vent Catheters should be removed
This communication is part of the Communications Pilot to Enhance the Medical Device Recall Program
Correction Issued for the Novum IQ Large Volume Pumps, Syringe Pumps
Correction Issued for the Novum IQ Large Volume Pumps, Syringe Pumps
FDA Approves First Immunotherapy for Recurrent Respiratory Papillomatosis
FDA approved Papzimeos, the first immunotherapy for use in adults with recurrent respiratory papillomatosis.
FDA Approves First Immunotherapy for Recurrent Respiratory Papillomatosis
FDA approved Papzimeos, the first immunotherapy for use in adults with recurrent respiratory papillomatosis.
FDA grants accelerated approval to zongertinib for non-squamous NSCLC
On August 8, 2025, the Food and Drug Administration granted accelerated approval to zongertinib (Hernexeos, Boehringer Ingelheim Pharmaceuticals, Inc.), a kinas
FDA Project Catalyst Accelerator Innovator Discussion Meeting Preliminary Registration
Take this survey powered by surveymonkey.com. Create your own surveys for free.
OCE Oncology News
A monthly newsletter for oncology/hematology fellows, junior faculty and scientists